Sartar Therapeutics is revolutionizing soft-tissue sarcoma therapy with their innovative precision medicine product, SAR001. Soft-tissue sarcomas are rare and often lethal cancers, with limited treatment options for metastatic tumors. However, SAR001 specifically targets the PDE3A protein, which is frequently expressed in soft-tissue tumors, including GIST.

The company's groundbreaking scientific discovery of phosphodiesterase 3 as a novel therapy target has paved the way for a new, highly targeted approach to treating these aggressive cancers. By utilizing PDE3 as a biomarker, Sartar Therapeutics can identify the right patients for this targeted therapy. Through their dedication to finding novel solutions for unmet medical needs, Sartar Therapeutics is giving new life and purpose to anagrelide, providing hope for patients and their families.

Contact them today to learn more about their impressive work in Helsinki, Finland